Agnete Brunsvik Fredriksen
Co-Founder, CSO & CBO Nykode Therapeutics
Seminars
Thursday 18th March 2027
From Tumor to Plasma: Using ctDNA to Select Neoepitopes & Track Response in Personalized Cancer Vaccines
3:15 pm
- Explaining how ctDNA is combined with tumor biopsy sequencing, matched blood normal and RNA sequencing to confirm that candidate neoepitopes are tumor-specific, abundant and worth targeting in a personalized vaccine
- Showing why selecting mutations carried by enough tumor cells matters for clinical efficacy, and how plasma analysis adds confidence where core biopsies may under sample the tumor
- Discussing monitoring the same mutations, and HPV16- specific ctDNA in HPV-driven cancers, during treatment, and correlating those changes with imaging and clinical response
